Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915020 | 1.00 | KMT2A (0.49) | KMT2ASMN1; SMN2POLBPLGPLAT | |
| SCHEMBL915731 | 0.99 | KMT2A (0.50) | KMT2ASMN1; SMN2POLBPLGPLAT | |
| SCHEMBL915987 | 0.99 | KMT2A (0.50) | KMT2ASMN1; SMN2POLBPLGPLAT | |
| SCHEMBL915989 | 0.99 | KMT2A (0.50) | KMT2ASMN1; SMN2POLBPLGPLAT | |
| SCHEMBL915151 | 0.99 | KMT2A (0.50) | KMT2ASMN1; SMN2POLBPLGPLAT | |
| SCHEMBL915874 | 0.99 | KMT2A (0.50) | KMT2ASMN1; SMN2POLBPLGPLAT | |
| SCHEMBL915872 | 0.99 | KMT2A (0.50) | KMT2ASMN1; SMN2POLBPLGPLAT | |
| SCHEMBL914977 | 0.86 | KMT2A (0.49) | KMT2ASMN1; SMN2POLBPLGPLAT | |
| SCHEMBL4696406 | 0.86 | KMT2A (0.49) | KMT2ASMN1; SMN2POLBPLGPLAT | |
| SCHEMBL914978 | 0.86 | KMT2A (0.49) | KMT2ASMN1; SMN2POLBPLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372881-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2013-02-12 | — | — | US | claimed |
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2011-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | ACMSD, APEH, CPS1 | KMT2A 1530/4885SMN1; SMN2 3931/4885POLB 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.